54 Capital Plans Ethiopian Pharma Factory After Deal

  • Ethiopia's $400 million drugs market growing at 25% a year
  • Foreign private-equity investments are increasing in Ethiopia

54 Capital, a London-based private-equity company, plans to build a new plant for Addis Pharmaceutical Factory within two years after investing $30 million in its seventh deal in Ethiopia, an executive said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.